씨젠

096530KOSDAQ의료용품 및 기타 의약 관련제품 제조업

60.1 / 100

Reference Date: 2026-07-24

Financial Score19.0 / 40

News Sentiment20.1 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 2.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Seegene is a molecular diagnostics specialist established in 2000, leveraging DNA/RNA analysis to detect disease causes, with 91% of its revenue from exports globally. The company utilizes its proprietary Syndromic qPCR technology and 19 patents to develop multiplex diagnostic products, and is expanding AI-driven diagnostic reagent development through collaborations with Microsoft and Springer Nature.

Number of Employees

822people

Average Salary

95.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

29.70Industry Average 15.181.5Point

2.0x industry avg (risky)

PBR

1.42Industry Average 1.092.5Point

Higher than industry avg (caution)

ROE

4.82Industry Average -4.893.5Point

Well below industry avg

Debt Ratio

4.85Industry Average 6.865.0Point

Lower than industry avg (good)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲177.4% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.0% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 8Neutral 0Negative 1Average Sentiment Score 80.6

Positive
씨젠, 3종 동시진단 제품 美 승인…1조 시장 정조준
씨젠의 다중 바이러스 동시진단 제품이 미국에서 긴급사용승인을 받아 시장 확대 기대감이 높아짐.
Positive
씨젠USA, 피부질환 동시진단 키트…FDA 긴급승인
씨젠USA의 새로운 피부질환 진단 키트가 FDA로부터 긴급 승인을 받으며 미국 시장 진출 가속화 기대.
Positive
씨젠USA 신드로믹 PCR 진단 제품, 美 FDA 긴급사용승인 획득
씨젠USA의 FDA 긴급사용승인 획득으로 씨젠의 글로벌 진단 제품 경쟁력 강화.

Detailed Momentum

52-week position5.0Point

52w mid range (56%)

Current 27,550Won52-week high 32,00052-week low 21,850

1-month return4.0Point

1m +2.23% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0